This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.62% per year. These returns cover a period from January 1, 1988 through June 2, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
earnings-consensus: Archive
Wall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Sagimet Biosciences Inc. (SGMT) points to a 437.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
SGMTPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 25.35% Upside in HubSpot (HUBS): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 25.4% in HubSpot (HUBS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
HUBSPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Vigil Neuroscience (VIGL) Could Surge 26.9%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 26.9% in Vigil Neuroscience (VIGL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
VIGLPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 107.4% upside potential for Phathom Pharmaceuticals (PHAT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
PHATNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Alvotech (ALVO) Could Surge 72.61%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 72.6% in Alvotech (ALVO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
ALVONegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 129.1% in Apogee Therapeutics Inc. (APGE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
APGEPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Concentra (CON) Could Rally 27.1%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 27.1% in Concentra (CON). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
CONPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 46.32% Upside in BILL Holdings (BILL): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 46.3% in BILL Holdings (BILL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
BILLNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Birkenstock (BIRK) Could Rally 25.79%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 25.8% in Birkenstock (BIRK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
BIRKNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 222.16%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 222.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
GLUEPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 30.05% Upside in Elastic (ESTC): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Elastic (ESTC) points to a 30.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ESTCNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 38.85% Upside in EverQuote (EVER): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for EverQuote (EVER) points to a 38.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
EVERPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 60.16% Upside in Oatly Group (OTLY): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 60.2% in Oatly Group (OTLY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
OTLYPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 556.2% upside potential for Silence Therapeutics (SLN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
SLNPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Euroseas (ESEA) Could Surge 32.26%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 32.3% upside potential for Euroseas (ESEA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ESEAPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
RH (RH) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
RH (RH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RHPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Does Brainsway (BWAY) Have the Potential to Rally 43.88% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Brainsway (BWAY) points to a 43.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
BWAYNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Green Dot (GDOT) Have the Potential to Rally 29.63% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Green Dot (GDOT) points to a 29.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
GDOTPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See an 180.53% Upside in Knightscope (KSCP): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Knightscope (KSCP) points to an 180.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
KSCPNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think LifeStance Health (LFST) Could Surge 45.04%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 45% upside potential for LifeStance Health (LFST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
LFSTNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 367.86% Upside in Verve Therapeutics (VERV): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 367.9% upside potential for Verve Therapeutics (VERV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
VERVPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Synaptics (SYNA) Have the Potential to Rally 40.62% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 40.6% upside potential for Synaptics (SYNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
SYNAPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
How Much Upside is Left in BioLife Solutions (BLFS)? Wall Street Analysts Think 41.72%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 41.7% in BioLife Solutions (BLFS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
BLFSPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 65.98% Upside in Benitec Biopharma (BNTC): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 66% in Benitec Biopharma (BNTC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
BNTCPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Natural Gas Services (NGS) Have the Potential to Rally 47.9% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Natural Gas Services (NGS) points to a 47.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
NGSNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate